Danaher Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Danaher wird ein jährliches Gewinn- und Umsatzwachstum von 13.8% bzw. 6.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.3% betragen.

Wichtige Informationen

14.3%

Wachstumsrate der Gewinne

14.6%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum17.6%
Wachstumsrate der Einnahmen7.0%
Zukünftige Eigenkapitalrendite10.9%
Analystenabdeckung

Good

Zuletzt aktualisiert01 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings

Aug 13
Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings

Danaher: Valuation Now Too High Even Compared To Own High Standards

Jul 16

What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?

Jun 23
What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?

Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum

Jun 20

Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?

Jun 05
Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?

Is Danaher (NYSE:DHR) A Risky Investment?

May 21
Is Danaher (NYSE:DHR) A Risky Investment?

It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year

May 01
It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year

Value Vs. Growth? Danaher Says Why Not Both?

Apr 25

Danaher: All In On Life Sciences, And Market Update

Mar 27

Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?

Mar 11
Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?

Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings

Feb 10
Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings

Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term

Jan 30

Is Danaher (NYSE:DHR) Using Too Much Debt?

Jan 12
Is Danaher (NYSE:DHR) Using Too Much Debt?

My Top 2024 Stock Pick: Danaher

Dec 27

Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles

Nov 26

RGA Investment Advisors - Danaher:  Purity In The Crown Jewel Of Bioprocessing

Nov 19

Why Danaher Is One Of My Favorite Long-Term Investments

Oct 26

Danaher: Short-Term Headwinds, But Long-Term Tailwinds

Oct 17

Should Danaher Investors Sell New Veralto Shares?

Oct 02

Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price

Sep 30
Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price

Danaher: A Lost Year

Aug 30

Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens

Aug 02

Danaher: A Compounding Icon At A Fair Price

Jul 25

These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well

Jul 13
These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Jun 28
Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump

Jun 22

At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?

Jun 15
At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?

Danaher: A Great Chance To Buy This Long-Term Compounder

May 23

With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case

Apr 26
With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case

Estimating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Mar 28
Estimating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Is Now The Time To Look At Buying Danaher Corporation (NYSE:DHR)?

Mar 15
Is Now The Time To Look At Buying Danaher Corporation (NYSE:DHR)?

Is Danaher (NYSE:DHR) Using Too Much Debt?

Mar 02
Is Danaher (NYSE:DHR) Using Too Much Debt?

Danaher ups dividend by 8% to $0.27

Feb 22

Gewinn- und Umsatzwachstumsprognosen

NYSE:DHR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202627,7245,8467,4088,47317
12/31/202525,6805,0826,5027,57822
12/31/202423,7764,2425,6916,34422
6/28/202423,5684,0565,0816,447N/A
3/29/202423,7374,0695,5486,956N/A
12/31/202323,8904,2005,7817,164N/A
9/29/202322,2754,5976,8318,086N/A
6/30/202323,0655,0197,2578,424N/A
3/31/202324,9045,7577,3648,498N/A
12/31/202226,6436,2227,4018,519N/A
9/30/202231,2506,6407,0688,311N/A
7/1/202230,8166,2067,0518,335N/A
4/1/202230,2836,2067,1628,455N/A
12/31/202124,8025,2837,1188,358N/A
10/1/202128,0655,6367,0568,246N/A
7/2/202126,7205,3616,8767,935N/A
4/2/202124,7994,5956,3517,260N/A
12/31/202022,2843,5105,4176,208N/A
10/2/202020,3923,0834,4445,099N/A
7/3/202018,8862,8533,7124,341N/A
4/3/202018,0342,6143,4394,068N/A
12/31/201917,9112,3643,3163,952N/A
9/27/201915,5622,0933,4794,078N/A
6/28/201916,0372,1453,4464,032N/A
3/29/201916,5732,1663,3113,896N/A
12/31/201817,0492,4063,4384,022N/A
9/28/201819,6152,7613,0043,619N/A
6/29/201819,2902,6693,1673,772N/A
3/30/201818,8192,553N/A3,747N/A
12/31/201715,5192,172N/A3,478N/A
9/29/201717,8282,360N/A3,292N/A
6/30/201717,4322,191N/A3,038N/A
3/31/201717,1642,051N/A3,309N/A
12/31/201616,8822,153N/A3,522N/A
9/30/201616,6211,927N/A4,104N/A
7/1/201616,0011,905N/A4,239N/A
4/1/201613,6631,775N/A4,051N/A
12/31/201514,4341,747N/A3,802N/A
10/2/201515,3351,875N/A3,810N/A
7/3/201516,5302,177N/A3,873N/A
4/3/201519,1862,521N/A3,771N/A
12/31/201412,8671,639N/A3,758N/A
9/26/201419,1972,683N/A3,597N/A
6/27/201419,1592,599N/A3,553N/A
3/28/201419,3362,583N/A3,460N/A
12/31/201318,2832,591N/A3,585N/A
9/27/201318,8272,536N/A3,307N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DHRDas prognostizierte Gewinnwachstum (13.8% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: DHRDie Erträge des Unternehmens (13.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: DHRDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: DHRDie Einnahmen des Unternehmens (6.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: DHRDie Einnahmen des Unternehmens (6.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DHRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.3%).


Wachstumsunternehmen entdecken